HC Wainwright & Co. Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Collegium Pharmaceutical and raised the price target from $47 to $50, indicating confidence in the company's future performance.
September 05, 2024 | 9:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has increased its price target for Collegium Pharmaceutical from $47 to $50, maintaining a Buy rating. This suggests a positive outlook for the company's stock.
The increase in price target from $47 to $50 by HC Wainwright & Co. reflects a positive sentiment and confidence in Collegium Pharmaceutical's future performance. The Buy rating suggests that the stock is expected to perform well, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100